Naples Global Advisors LLC Decreases Stock Position in Sanofi $SNY

Naples Global Advisors LLC decreased its position in Sanofi (NASDAQ:SNY) by 3.4% in the 2nd quarter, Holdings Channel reports. The fund owned 11,337 shares of the company’s stock after selling 400 shares during the period. Naples Global Advisors LLC’s holdings in Sanofi were worth $548,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sanofi by 124.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock valued at $1,344,000 after purchasing an additional 13,358 shares during the last quarter. Axxcess Wealth Management LLC grew its position in shares of Sanofi by 130.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company’s stock valued at $568,000 after buying an additional 5,794 shares during the last quarter. Ballentine Partners LLC raised its position in shares of Sanofi by 68.7% during the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company’s stock worth $1,445,000 after purchasing an additional 10,617 shares during the period. Voya Investment Management LLC increased its position in Sanofi by 11.6% in the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock worth $11,460,000 after buying an additional 21,540 shares during the period. Finally, Sowell Financial Services LLC bought a new stake in Sanofi in the 1st quarter valued at about $328,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $50.90 on Friday. The business has a 50 day moving average price of $48.19 and a 200 day moving average price of $50.09. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a market cap of $124.99 billion, a price-to-earnings ratio of 12.24, a PEG ratio of 1.19 and a beta of 0.51. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same quarter last year, the firm earned $1.73 earnings per share. The firm’s quarterly revenue was down 7.0% compared to the same quarter last year. Research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a report on Saturday, September 27th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Finally, JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.